TABLE 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazon

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Placebo group | Troglitazone group | | | | P |
| *N* | 122 | 114 | | | |  |
| Clinical characteristics | | | | | | |
| Age (years) | 34.3 ± 6.5 | 34.9 ± | 6.6 | | | 0.52 |
| BMI (kg/m2) | 30.3 ± 5.3 | 6.10 ± | 0.06 | | | 0.63 |
| Waist-to-hip circumference ratio | 0.86 ± 0.05 | 30.6± | 0.85 | | | 0.19 |
| Using hormonal contraceptives\* | 48% | 43% |  | | | 0.41 |
| OGTT† | | | | | | |
| Fasting glucose (mg/dl) | 98.1 ± 9.1 | 98.7 ± | | | 10.2 | 0.64 |
| 2-h glucose | 154.0 ± 24.0 | 154.4 ± | | | 27.0 | 0.97 |
| Total glucose area (mg/dl × min × 10-3)‡ | 18.7 ± 2.0 | 18.9 ± | | | 2.0 | 0.25 |
| Impaired glucose tolerance§ | 72% | 69% | | |  | 0.66 |
| Fasting insulin (U/ml) | 16.0 ± 7.5 | 17.0 ± | | | 10.8 | 0.82 |
| Total insulin area (U/ml × min)‡ | 10,209 ± 5536 | 9,902 ± 6,543 | | |  | 0.55 |
| IVGTT | | | | | | |
| Fasting glucose (mg/dl) | 94.3 ± 10.4 | 94.8 ±10.2 | |  | | 0.71 |
| Kg (min-1× 100)¶ | 1.48 ± 0.40 | 1.42 ± 0.39 | |  | | 0.23 |
| Fasting insulin (U/ml) | 18.7 ± 9.7 | 16.6 ± 9.5 | |  | | 0.05 |
| Si(min-1per U/ml × 10×4)# | 2.28 ± 1.75 | 2.64 ± 1.70 | |  | | 0.05 |
| AIRg (U/ml × min)\*\* | 569 ± 527 | 454 | | ± 360 | | 0.18 |
| Total insulin area (units/ml × min)‡ | 10,686 ± 5686 | 9,273 ± 5434 | |  | | 0.03 |
| DI (SI × AIRg)†† | 983 ± 697 | 976 ± 717 | |  | | 0.99 |